Creating Access to Psilocybin-assisted Therapy for palliative care
Since July 2023, psilocybin and MDMA-assisted therapy have been available in Australia as part of the Therapeutic Goods Administration’s (TGA’s) Authorised Prescriber program.
Psychiatrists who have completed specialist training in psychedelic-assisted therapy can apply to become an Authorised Prescriber. Access is limited to treatment-resistant depression (psilocybin) and PTSD (MDMA).
On March 7th 2025, The End Wise Coalition submitted an application to amend the regulations, allowing psilocybin to also be prescribed for those diagnosed with a terminal illness who are suffering from existential distress.
The application had a public consultation period in May, and an interim decision will be announced in September. A second public consultation period will take place after the interim decision is announced, before a final decision is made.
Below you can read our application to allow access to psilocybin for those suffering from existential distress towards the end of their lives.
Collaborators & Supporters
-
Mind Medicine Australia provided guidance on the TGA application on the basis of their successful application for the re-classification of psilocybin and MDMA in 2023.
-
The Ethics Centre played a pivotal role in catalysing the formation of the End Wise Coalition, offering not only residency space but principled guidance rooted in ethical inquiry, helping to shape the Coalition’s foundations with clarity, courage, and compassion.
-
PsiloNautica guided the Coalition through the complexities of the psychedelic sector, offering expertise on the safe and ethical application of psychedelics in palliative medicine.